Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company's oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, which is in Phase I; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases, and APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain, which is in preclinical development. In June 2012, the United States Food and Drug Administration approved its internally discovered drug, BELVIQ.
|Headquarters||6154 Nancy Ridge Drive|
SAN DIEGO, CA, United States 92121
|Chairman of the Board, President, Chief Executive Officer||Jack Lief|
|Chief Financial Officer, Principal Financial Officer, Vice President - Finance, Principal Accounting Officer||Robert Hoffman|
|Executive Vice President, Chief Scientific Officer, Director||Dominic Behan|
|Executive Vice President, General Counsel, Secretary||Steven Spector|
|Senior Vice President, Chief Medical Officer||William Shanahan|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||217.8M||Book Value||$0.45|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||62.6|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-227.51%|
*GAAP = prior to non-GAAP analyst adjusted earnings.